Estimation of covid-19 cases in france and in different countries: homogeneisation based on mortality

Chaque jour une estimation du nombre de personnes touchées par le Covid-19 et un décompte de la mortalité sont effectués par les autorités de différents pays. Nous proposons que la mortalité rapportée dans chaque pays puisse être utilisée pour créer un indice du nombre de cas réels à un temps t0. Cet indice est: Ct0-estimé = (Mt0 / Mt-est) * (Mt0 / Mt0-3j)6 Avec Mt0 : nombre de morts rapportés dans un pays au temps t0 ; Mt0-3j : nombre de morts rapportés dans un pays au temps t0 moins 3 jours; Mt-est : Taux de mortalité estimé. En utilisant un taux de mortalité estimé de 2%, nous avons évalué le nombre de cas le 10 avril 2020 en Allemagne, Belgique, Chine, Corée du Sud, Espagne, France, Iran, Italie, Pays-Bas, Royaume-Uni et aux USA. Ce nombre atteignait 2 872 097 en France et 924 892 personnes en Allemagne. Ce travail suggère une très forte sous-estimation du nombre de cas de personnes touchées, avec un indice de notification souvent inférieur à 5%. La formule proposée permet également d’évaluer l’impact de politiques de prévention de la dissémination du virus.Every day authorities of different countries provide an estimate of the number of persons affected by Covid-19 and a count of fatality. We propose to use the fatality reported in each country to provide a better estimate (Ct0-estimated) of the number of cases at a given time t0. Ct0-estimated = (Mt0 / Mt-est) * (Mt0 / Mt0-3j)6 With Mt0: number of fatalities reported in a country at time t0; Mt0-3j: number of fatalities reported in a country at time t0 minus 3 days; Mt-est: estimated fatality rate. Based on a fatality rate of 2%, we assessed the number of cases Avril 10th 2020 in Belgium, China, France, Germany, Iran, Italy, South Korea, Netherlands, Spain, United Kingdom and USA. This number reached 2,872,097 in France and 924,892 persons in Germany. This work suggests a very strong underestimation of the number of cases of people affected, with a notification index often less than 5%. The proposed formula also makes it possible to evaluate the impact of policies to prevent the spread of epidemic

Malignant pleural mesothelioma subtypes

Review of histologic subtypes of mesothelioma, with associated clinical, pathologic, and molecular data

BIRC8 (baculoviral IAP repeat containing 8)

BIRC8, also known as ILP-2, is a homologous protein of BIRC4, however, its function has seldom been addressed. Despite the similarity with other Inhibitory Apoptosis Proteins (IAPs), there is evidence that BIRC8 acts in a peculiar manner, by impeding apoptosis induced by BAX without directly inhibiting the activity of caspases. BIRC8 expression has been detected in testis and lymphoblastic normal cells and, furthermore, it has been reported in different cancers, including breast carcinoma, hematological neoplasms, hepatocellular carcinoma, nasopharyngeal carcinoma, and neuroblastoma. However, the specific implications of such protein for treatment and prognosis must be further evaluated. In this review, current data on RNA, DNA, protein and the association of BIRC8 in cancer are presented

Langerhans cell histiocytosis

Tumours derived from Langerhans cells (LCs) are divided into two main subgroups, according to the degree of cytological atypia and clinical aggressiveness: LC histiocytosis (LCH) and LC sarcoma. Both subgroups maintain the phenotypic profile and ultrastructural features of LCs. LCH is a clonal neoplastic proliferation of Langerhans-type cells that express CD1a, langerin, and S100 protein, showing Birbeck granules by ultrastructural examination. Here the clinicopathological of LCH will be discussed

t(6;10)(q22;q24) NFKB2/ROS1

Review on t(6;10)(q22;q24), with data on the genes involved

CRLF2 (Cytokine receptor like factor 2)

CRLF2 is a member of type I cytokine receptor family. CRLF2 forms a functional complex with IL-7 receptor α chain and thymic stromal lymphopoietin, this complex induces the activation of signal transducers and activators of transcription proteins. The overexpression of CRLF2 induced by genetic rearrangements has been described in acute lymphoblastic leukemia